"Angiotensin II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS.
| Descriptor ID |
D000804
|
| MeSH Number(s) |
D06.472.699.094.078 D12.644.400.070.078 D12.644.456.073.041 D12.644.548.058.078 D12.776.631.650.070.078 D23.469.050.050.050
|
| Concept/Terms |
Angiotensin II- Angiotensin II
- ANG-(1-8)Octapeptide
- Angiotensin-(1-8) Octapeptide
Angiotensin II, Ile(5)-- Angiotensin II, Ile(5)-
- Angiotensin II, Isoleucine(5)-
- 5-L-Isoleucine Angiotensin II
- 5 L Isoleucine Angiotensin II
- Angiotensin II, 5-L-Isoleucine
- Isoleucine(5)-Angiotensin
- Isoleucyl(5)-Angiotensin II
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin II".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin II".
This graph shows the total number of publications written about "Angiotensin II" by people in this website by year, and whether "Angiotensin II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 2 | 3 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiotensin II" by people in Profiles.
-
Effect of genetic depletion of MMP-9 on neurological manifestations of hypertension-induced intracerebral hemorrhages in aged mice. Geroscience. 2021 10; 43(5):2611-2619.
-
Angiotensin II and Vasopressin for Vasodilatory Shock: A Critical Appraisal of Catecholamine-Sparing Strategies. J Intensive Care Med. 2021 Jun; 36(6):635-645.
-
IGF-1 Deficiency Promotes Pathological Remodeling of Cerebral Arteries: A Potential Mechanism Contributing to the Pathogenesis of Intracerebral Hemorrhages in Aging. J Gerontol A Biol Sci Med Sci. 2019 03 14; 74(4):446-454.
-
When All Else Fails: Novel Use of Angiotensin II for Vasodilatory Shock: A Case Report. A A Pract. 2018 Oct 01; 11(7):175-180.
-
Insulin-like growth factor 1 deficiency exacerbates hypertension-induced cerebral microhemorrhages in mice, mimicking the aging phenotype. Aging Cell. 2017 06; 16(3):469-479.
-
Circulating IGF-1 deficiency exacerbates hypertension-induced microvascular rarefaction in the mouse hippocampus and retrosplenial cortex: implications for cerebromicrovascular and brain aging. Age (Dordr). 2016 Aug; 38(4):273-289.
-
Cross talk between MMP2-Spm-Cer-S1P and ERK1/2 in proliferation of pulmonary artery smooth muscle cells under angiotensin II stimulation. Arch Biochem Biophys. 2016 08 01; 603:91-101.
-
AT2R autoantibodies block angiotensin II and AT1R autoantibody-induced vasoconstriction. Hypertension. 2015 Oct; 66(4):830-5.
-
IGF-1 deficiency impairs cerebral myogenic autoregulation in hypertensive mice. J Cereb Blood Flow Metab. 2014 Dec; 34(12):1887-97.
-
Role of 20-HETE, TRPC channels, and BKCa in dysregulation of pressure-induced Ca2+ signaling and myogenic constriction of cerebral arteries in aged hypertensive mice. Am J Physiol Heart Circ Physiol. 2013 Dec; 305(12):H1698-708.